Clinical trial · no report yet · Phase 2

REJOICE-PanTumor01

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654 ↗
Active, not recruiting
Daiichi Sankyo
Standard

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
YouTube	8
Podcasts	5
X threads	1

The trial

ClinicalTrials.gov

Official title: REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors
Phase: Phase 2
Status: Active, not recruiting
Conditions: Advanced Solid Tumor; Metastatic Solid Tumors
Interventions: Raludotatug deruxtecan
Arms: Endometrial Cancer Cohort · Experimental
Cervical Cancer Cohort · Experimental
Non-high-grade Serous Ovarian Cancer · Experimental
Urothelial Cancer Cohort · Experimental
Clear Cell Renal Carcinoma (ccRCC) Cohort · Experimental
Enrollment: 335 (estimated)
Primary outcomes: Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)
Disease Control Rate (DCR) as Assessed by the Investigator (ccRCC Cohort Only)
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts)
Sponsor: Daiichi Sankyo with Merck Sharp & Dohme LLC
Start: Jan 6, 2025
Primary completion: Dec 30, 2029 (estimated)
Results posted: No
Registry record: NCT06660654 · updated Sep 24, 2026